Validating an EEG-based test for ADHD: a casecontrol study on brain connectivity during executive task

Recruitment status	Prospectively registered		
No tonger recruiting	[] Protocol		
Overall study status	Statistical analysis plan		
Completed Condition category	[] Results		
	Individual participant data		
Mental and Behavioural Disorders	[X] Record updated in last year		
	Recruitment status No longer recruiting Overall study status Completed Condition category Mental and Behavioural Disorders		

Plain English summary of protocol

Background and study aims

Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition that affects about 5-7% of children and 2-5% of adults worldwide. It is characterized by symptoms like inattention, hyperactivity, and impulsivity. Diagnosing ADHD can be challenging because there is no specific medical test for it, and current methods rely heavily on clinical interviews and behavioral assessments, which are subjective and can lead to misdiagnosis. This study aims to improve the accuracy of ADHD diagnosis by using brain activity data collected through electroencephalograms (EEGs). Researchers will analyze brain connectivity patterns during tasks that require executive control, using advanced computer algorithms to identify specific biomarkers (biological indicators) associated with ADHD. The goal is to develop an EEGbased diagnostic tool that can accurately identify ADHD in children.

Who can participate?

The study will involve at least 162 children aged between 7 and 12 years. Participants will be divided into three groups:

- Children diagnosed with ADHD, predominantly inattentive type.

- Children diagnosed with ADHD, predominantly combined or hyperactive type.

- Healthy children without ADHD, who are serving as the control group.

Children must have the consent of their parents or guardians to participate. Some medical conditions or the use of certain medications may exclude children from the study to ensure accurate results.

What does the study involve?

Participants will undergo several assessments:

- Clinical Interview: To gather detailed medical and behavioral history.

- Neuropsychological Tests: To evaluate cognitive functions like attention, memory, and problemsolving.

- EEG Recording: To measure brain activity while the child is at rest and during a simple attention task called the "go/no-go" task.

The EEG cap with 64 sensors will record the brain's electrical activity. The task will involve

responding to certain visual stimuli on a computer screen, designed to engage attention and impulse control.

What are the possible benefits and risks of participating? Benefits:

- Participants will receive a thorough assessment of their cognitive and brain function, which may help in understanding their attention-related difficulties.

- The study may contribute to the development of a new, more accurate diagnostic tool for ADHD, potentially benefiting many children in the future. Risks:

- The procedures are safe and non-invasive. EEG is commonly used in clinical settings and poses no known risks.

- Some children might feel uncomfortable wearing the EEG cap or sitting still during the test. Breaks will be provided to minimize discomfort.

Where is the study run from?

The study is conducted at the Puerta de Hierro Hospital in Majadahonda, Madrid, Spain.

When is the study starting and how long is it expected to run for? The study started in June 2023 and is expected to run until November 2024. The analysis of the collected data will continue until early 2025, with results anticipated in the first half of 2025.

Who is funding the study?

The study is funded by the sponsor, Bitsphi Diagnosis. Specific details about the sponsor are managed by the study's administrative team.

Who is the main contact? Sandra Ortiz Hernández (Clinical Trial Manager), bitsphiclinico@bitsphi.com

Study website

https://bitsphi.com/clinical-trials/

Contact information

Type(s) Principal Investigator

Contact name Mr Javier Sánchez

Contact details

Joaquín Rodrigo, 2 Majadahonda, Madrid Spain 28222 +34685742120 bitsphiclinico@bitsphi.com

Type(s) Public, Scientific

Contact name

Ms Sandra Ortiz

Contact details

Gobelas 17 Madrid Spain 28023 917081076 bitsphiclinico@bitsphi.com

Additional identifiers

EudraCT/CTIS number Nil known

IRAS number

ClinicalTrials.gov number Nil known

Secondary identifying numbers HUPH-BP-BMCCEEG-CC22

Study information

Scientific Title

Retrospective/prospective case-control study to determine the concurrent criterion validity of a diagnostic test for attention-deficit/hyperactivity disorder based on the classification of brain connectivity patterns evoked during an executive control challenge

Acronym SINCRONIA

Study objectives

The characterization, refinement, and concurrent validation of an ADHD diagnostic test based on biomarkers of attentional control and executive function will identify the minimal set of brain connectivity patterns that optimize diagnostic performance. Furthermore, the index test will demonstrate non-inferiority or superiority compared to the best available reference standard.

Ethics approval required

Ethics approval required

Ethics approval(s)

Approved 16/02/2023, Drug Research Ethics Committee of the Puerta de Hierro University Hospital (Joaquín Rodrigo, 2, Majadahonda, Madrid, 28222, Spain; +3491 191 76 62; secreceic. hpth@salud.madrid.org), ref: 207/22

Study design

Non-interventional case-control cross-sectional non-randomized blinded study

Primary study design

Observational

Secondary study design Case-control study

Study setting(s) Hospital

Study type(s) Diagnostic

Participant information sheet

Not available in web format, please use contact details to request a participant information sheet.

Health condition(s) or problem(s) studied

Attention deficit/hyperactivity disorder (ADHD)

Interventions

This is an observational study investigating electroencephalogram (EEG)-based biomarkers for ADHD diagnosis in children aged 7 to 12.

Participants undergo a comprehensive assessment that includes clinical interviews, standardized neuropsychological tests (such as the WISC-V for intelligence; CPT-3 and ENFEN for attention, processing speed, and executive functions; SDQ, CABI, and ADHD Rating Scale-IV for behavioral and emotional regulation; PROLEXIA for dyslexia screening; and CCI-2 for slow cognitive tempo), alongside EEG recordings during both resting state and a go/no-go interference task with varying stimulus ratios to evaluate brain connectivity, response inhibition, and cognitive control.

Intervention Type

Other

Primary outcome measure

The diagnostic accuracy of the EEG-based index test for ADHD, defined by its sensitivity (true positive fraction) and specificity (false positive fraction). These metrics are derived from EEG functional connectivity patterns recorded during a standardized go/no-go interference task.

Secondary outcome measures

1. Comparison with CPT-3 Performance measured by comparing classification probabilities (e.g., sensitivity and specificity) of the EEG-based index test with those obtained from the Continuous Performance Test (CPT-3).

2. Influence of Demographic and Clinical Factors assessed via regression analyses correlating participant characteristics (such as age, sex, ADHD subtype, and comorbidities) with the diagnostic performance metrics.

3. Construct Validity of Slow Cognitive Tempo (SCT) measured using scores from the Child Concentration Inventory-Version 2 (CCI-2) and correlating these with EEG biomarkers.

4. EEG Biomarker Identification determined through dimensional reduction techniques and fuzzy deep neural network analyses to identify the most informative EEG connectivity metrics.

Overall study start date

01/01/2023

Completion date

12/11/2024

Eligibility

Key inclusion criteria

1. Aged between 7 and 12 years (inclusive).

2. Right-handed dominance.

3. Written informed consent from a legal representative and assent from the participant.

4. (Cases) Diagnosed with ADHD within the past 3 years or at the time of the study, with hyperactive/impulsive, combined, or inattentive presentation, including cases with dyslexia or slow cognitive tempo (SCT).

5. (Controls) Patients from the Pediatrics Department at HUPHM, whose medical care will not be compromised by participation (e.g., those monitored for short stature, hypercholesterolemia, early pubarche, or heart murmurs/chest pain).

Participant type(s)

Patient

Age group Child

Lower age limit 7 Years

Upper age limit 12 Years

Sex Both

Target number of participants 162

Total final enrolment 189

Key exclusion criteria

1. Color blindness or any other condition affecting sensorineural perception, which may interfere with study procedures.

2. Cognitive or behavioral difficulties (pathological or not) or insufficient capacity, as determined by the investigator, to maintain a minimum level of relaxation and rest or to understand and follow study procedures.

3. Regular use of medications (excluding ADHD treatment) that may affect attentional or executive function, such as opioid analgesics, benzodiazepines, hypnotics, or sedative antihistamines, or any other drug deemed relevant by the investigator.

4. (Cases) Subjects for whom stopping ADHD medication for 24 hours (methylphenidate

/atomoxetine) or 48 hours (other ADHD medications) poses a medical, behavioral, or other risk. 5. (Cases) Subjects for whom a medication change (different drug) was required after initial stabilization for clinical stabilization reasons, except for adjustments made during holidays or weekends.

6. Diagnosis of ADHD subtypes not considered in the inclusion criteria or presence of other neurological or psychiatric disorders significant enough to interfere with study evaluations, such as autism spectrum disorders, Tourette's syndrome, or epilepsy (or epileptic foci).

7. (Control) Participants who meet the diagnostic criteria for ADHD or other significant mental health conditions, as determined by the research team using DSM-5 criteria and the SDQ questionnaire.

Date of first enrolment 18/07/2023

Date of final enrolment 12/11/2024

Locations

Countries of recruitment Spain

Study participating centre Puerta de Hierro University Hospital Joaquín Rodrigo, 2 Majadahonda, Madrid Spain 28222

Sponsor information

Organisation Bitsphi Diagnosis

Sponsor details

Gobelas 17 Madrid Spain 29023 +34 917081076 bitsphiclinico@bitsphi.com

Sponsor type

Industry

Website

https://bitsphi.com/

Funder(s)

Funder type Industry

Funder Name Bisphi Diagnosis

Results and Publications

Publication and dissemination plan

Planned publication in a peer-reviewed journal.

Intention to publish date

01/11/2025

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to their use in training proprietary algorithms that will be part of a commercial diagnostic product and to protect participant confidentiality and intellectual property rights.

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	version 1.0	12/12/2022	19/02/2025	No	Yes